3D Stack HepG2 Liver-chip-model
Characterisation Data
Enhanced Hepatic Function on 3D Stack Liver Model
Imaging of cells through 3D stacked liver-chip layers
Cells were imaged live on day 3 in stacked layers using epi-fluorescent microscopy (10x magnification). Labling: HUVEC with Cell Tracker (Green, CMFDA), HepG2 cells with Cell Tracker (Red, CMTPX) and NIN/3T3 cells with Hoechst stain. Cells can be easy imaged through layers by standard inverted microscope
Metabolism in HepG2 hepatocytes
CYP3A4 expression levels in monoculture hepatocytes vs. tri-culture stacked set-up in CELLBLOKS®. In HepG2 heptocyes CYP3A4 activity increased 3 times compared to HepG2 monocultures.
Metabolism in human upcyte® primary hepatocytes
CYP3A4 expression levels in monoculture hepatocytes vs. tri-culture stacked set-up in CELLBLOKS®. In tri-culture model CYP3A4 in primary hepatocytes is enhanced by up to 3 times compared to monoculture hepatocytes over the 12 day of culture
Powerful Drug Induced Liver Injury (DILI) prediction capability
CELLBLOKS® 3D stack Liver-on-a-Chip model clearly distinguishes between hepatotoxic vs. their no-toxic structural analogues drugs at clinically relevant concentrations
Hepatotoxicity evaluation (24 h exposure) in CELLBLOKS® NANOSTACK™ based 3D liver model
Hepatotoxic drug-induced toxicity in HepG2 cells can be detected at concentrations < 10 µM over human plasma Cmax levels. The model correctly differentiated the hepatotoxic effects of compounds at high DILI concern (Clozapine, Troglitazone, Trovafloxacin) as opposed to their non-toxic drug analogues (respectively Olanzapine, Pioglitazone, Levofloxacin) at clinically relevant concentrations, therefore demonstrating a robust DILI prediction capability.